Lebrikizumab Demonstrates Consistent Efficacy at 16 Weeks in Patients With Moderate-to-Severe Atopic Dermatitis Regardless of Baseline Disease Severity. J of Skin. 2023;7(6):s274. doi:10.25251/skin.7.supp.274